Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK reports positive...

    GSK reports positive data from trial of cancer drug Dostarlimab

    GarimaWritten by Garima Published On 2019-03-21T09:15:38+05:30  |  Updated On 17 Aug 2021 11:49 AM IST




    GSK said it would apply for marketing approval for Dostarlimab in endometrial cancer at the end of 2019.

    New Delhi: GlaxoSmithKline said on Tuesday a study testing its experimental drug Dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

    Results from the GARNET study showed the drug elicited clinically meaningful and durable response rates when used to treat certain types of tumours, the company said.

    Read Also: GSK Consumer profit rises 35 percent to Rs 221.06 crore in December quarter

    GSK said it would apply for marketing approval for Dostarlimab in endometrial cancer at the end of 2019.

    Dostarlimab was developed as part of a collaboration between Tesaro and AnaptysBio Inc.

    GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.

    Read Also: HUL expects to complete merger with GSK Consumer Healthcare in 2019



    Anaptys Biocancercancer drugcancer in womencancer specialistCollaborationDostarlimabdrug dostarlimabendometrial cancerendometrial cancer drugGARNET studyGlaxoSmithKlineGSKGSK reportmedicinesovarian cancer Zejulapharma newsTesaroU SUnited StatesUS cancer specialist
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok